Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase I, Open-label, Multicenter, Dose Escalation, Multidose Study of BMS-936559 (MDX-1105) Administered Every 14 Days in Subjects with Selected Advanced or Recurrent Solid Tumors

Next Previous
Trial Profile

A Phase I, Open-label, Multicenter, Dose Escalation, Multidose Study of BMS-936559 (MDX-1105) Administered Every 14 Days in Subjects with Selected Advanced or Recurrent Solid Tumors

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 09 Nov 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs BMS 936559 (Primary)
  • Indications Breast cancer; Colorectal cancer; Gastric cancer; Malignant melanoma; Non-small cell lung cancer; Ovarian cancer; Pancreatic cancer; Renal cell carcinoma
  • Focus Adverse reactions
  • Acronyms Anti-PDL-1
  • Sponsors Bristol-Myers Squibb

Most Recent Events

  • 04 Sep 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
  • 27 Apr 2015 Planned End Date changed from 1 Jan 2015 to 1 Jul 2015 as reported by ClinicalTrials.gov record.
  • 27 Apr 2015 Planned primary completion date changed from 1 Jan 2015 to 1 Jul 2015 as reported by ClinicalTrials.gov record.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top